NEU-P11

[Sar9,Met(O2)11]-Substance P acetate is a tachykinin NK1 receptor selective agonist. [Sar9,Met(O2)11]-Substance P acetate is a selective tachykinin NK1 receptor agonist.[Sar9,Met(O2)11]-Substance P acetate and septide (10-100 pmol per rat, i.c.v.) are equipotent in increasing mean arterial blood pressure (MAP) and heart rate (HR), yet they have dissimilar time-course. Both agonists increase dose-dependently face washing and sniffing while [Sar9,Met(O2)11]-Substance P acetate is the sole to produce grooming.

Substance P (7-11) (Substance P 7-11(TFA)) is a C-terminal fragment of Substance P .

[Sar9,Met(O2)11]-Substance P (NA) is an NK1 receptor agonist.

Substance P (2-11), a fragment peptide of Substance P (SP), exhibits contractile effects on the guinea pig ileum and inhibits the permeation of tritiated SP (3 H SP) across brain microvessel endothelial cell (BBMEC) monolayers [1] [2].

Substance P (6-11), the C-terminal hexapeptideamide of Substance P, exhibits affinity for the NK-1 tachykinin receptor, leading to motoneuron depolarization and a hypotensive effect [1] [2].

[Glp5,Sar9] Substance P (5-11) is an analogue of Substance P [1].

[Glp5] Substance P (5-11), an octapeptide, is a key fragment of substance P in the rat central nervous system (CNS) and plays a localized role in modulating dopamine release in the rat striatum [1].

[Sar9,Met(O2)11]-Substance P TFA is a selective tachykinin NK1 receptor agonist.[Sar9,Met(O2)11]-Substance P and septide (10-100 pmol per rat, i.c.v.) are equipotent in increasing mean arterial blood pressure (MAP) and heart rate (HR), yet they have dissi

[D-Pro4,D-Trp7,9] Substance P (4-11) acts as a potent Substance P antagonist, significantly reducing plasma aldosterone (ALDO) concentrations[1].

Substance P (3-11), an SP fragment peptide capable of crossing the blood-brain barrier (BBB), induces contraction in guinea pig ileum and facilitates chemotaxis in human monocytes [1] [2] [5].

[DAla4] Substance P (4-11), an analog of Substance P (Substance P), effectively inhibits the binding of 125I-Bolton Hunter-conjugated Eledoisin (Eledoisin) and 125I-Bolton Hunter-conjugated Substance P to rat brain cortex membranes, with IC50 values of 0.5 μM and 0.15 μM, respectively [1].

Substance P (5-11), the C-terminal heptapeptide derived from Substance P, functions as a neuropeptide that specifically interacts with the NK-1 tachykinin receptor [1].

[D-Pro4,D-Trp7,9,10] Substance P (4-11) is a potent antagonist of the tachykinin family of neuropeptides [1].

[Sar4] Substance P (4-11) is a Substance P agonist and an analog of the C-terminus fragment of Substance P known as Substance P (4-11) [1].

Substance P (4-11), a C-terminal fragment of Substance P, acts as a highly selective agonist for NK1 receptors, demonstrating specificity in its interaction.

[Glp6] Substance P (6-11) is an analogue of the native peptide Substance P (6-11), acting on 'septide-sensitive' tachykinin receptors and stimulating the formation of [3H]-inositol monophosphate ([3H]-IP1) in rat urinary bladder, as evidenced by references [1] [2].

[Glp5,(Me)Phe8,Sar9] Substance P (5-11) (DiMe-C7) is an analogue of Substance P that acts on the neurokinin 1 receptor (NK1R) in rat brain, similarly to Substance P but with a significantly extended duration of action. This compound selectively enhances dopamine metabolism within the mesencephalon and midbrain cortex, increases motor activity, and facilitates the resumption of addictive agent-seeking behavior in rats [1] [2] [3].

[D-Pro4,D-Trp7,9,Nle11] Substance P (4-11) is a potent neurokinin NK1 antagonist that effectively inhibits the actions of gold-protein-substance P (GPSP) and substance P (SP), demonstrating its efficacy in neutralizing their effects [1].